Carnegie

Occlutech, founded in 2003, is a rapidly expanding European hi-tech company specializing in developing and manufacturing cardiac occlusion devices and other vascular implants. The company has developed several new, unique products using a wide range of state of the art technological capabilities and proprietary know-how.

Doktor.se is a modern and personal care company working with digital healthcare. They are in an expansive phase, they have several offices in Sweden and grow sharply. With experienced specialist nurses, doctors and psychologists, they help their members to get quick and effective care. Their goal is to deliver a whole new level of service within Swedish care. They help you with: counseling, book doctor hours, distance care, recipes, referrals and much more. They always follow every case. In their app, They also provide you with exclusive care and health offers as well as collecting interesting articles and news that will suit you and your family. Doktor.se is an approved healthcare provider. Counseling and booking is carried out by certified healthcare professionals and specialists in their area. Doktor.se also owns physical primary care and has extensive experience in Swedish healthcare.

Doktor.se is a modern and personal care company working with digital healthcare. They are in an expansive phase, they have several offices in Sweden and grow sharply. With experienced specialist nurses, doctors and psychologists, they help their members to get quick and effective care. Their goal is to deliver a whole new level of service within Swedish care. They help you with: counseling, book doctor hours, distance care, recipes, referrals and much more. They always follow every case. In their app, They also provide you with exclusive care and health offers as well as collecting interesting articles and news that will suit you and your family. Doktor.se is an approved healthcare provider. Counseling and booking is carried out by certified healthcare professionals and specialists in their area. Doktor.se also owns physical primary care and has extensive experience in Swedish healthcare.

Agilyx AS specializes in the chemical recycling of challenging post-use plastics, transforming them into valuable products such as new plastics, chemical intermediates, and low carbon fuels. Founded in 2004 and based in Tigard, Oregon, the company utilizes advanced recycling technology and an intelligent feedstock management system to convert mixed plastic waste into virgin-equivalent materials. Agilyx's processes include converting non-recyclable plastics, like styrofoam, into various applications that serve industries such as pharmaceuticals, agriculture, and construction. The company operates through two segments, Agilyx and Cyclyx, with a significant portion of its revenue generated from the Cyclyx segment, which focuses on waste sourcing and processing. By facilitating the conversion of plastic waste into valuable resources, Agilyx plays a crucial role in promoting a circular economy.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest such population worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.

ZoomON's software enables anyone with a browser to view, mark-up, design and collaborate on complex, and simple, graphics. This includes maps, product drawings and product catalogs. Their software cuts across proprietary technologies and unleashes the details anytime, anywhere!

Cylex is a life science company and a leader in the development and manufacture of unique products that use the immune system for predicting and managing human health. It is the first and only company to offer a patent- protected, FDA-cleared cellular assay of immune system function, ImmuKnow(TM), which measures the vitality of a patient's immune system from a single drop of blood. The company's products enable physicians to better manage and personalize the treatment of life-threatening diseases, such as HIV, HCV, cancer, diabetes, autoimmune and other disorders, as well as serious conditions associated with organ transplantation.